Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vudalimab in Metastatic Anaplastic Thyroid Cancer and Hurthle Cell Thyroid Cancer
NCT05453799Phase 2Suspended
- Sponsor
- Northwestern University
- Start
- Jul 2022
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vudalimab in anaplastic thyroid cancer (ATC), Hurthle cell carcinoma, sponsored by Northwestern University. Started Jul 2022; status: suspended.
02
Drugs
vudalimab
03
Conditions
anaplastic thyroid cancer (ATC)Hurthle cell carcinoma
Beyond the preview
Go deeper on NCT05453799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05453799.